GH1 and type 1 diabetes mellitus: In T1D, intraperitoneal administration of exogenous insulin has a more pronounced effect on the dysregulated IGF system than that of subcutaneous insulin, that is, increasing circulating IGF-1 and decreasing GH and IGFBP-1 more than subcutaneous insulin therapy [12].